ABSTRACT
Background In the field of immuno-oncology, predicting treatment response or survival of cancer patients remains a challenge. Efforts to overcome these challenges focus mainly on the discovery of new biomarkers. Owing to the complexity of cancers and their tumor microenvironment, only a limited number of candidate biomarkers eventually enters clinical practice, despite advances in cellular and molecular approaches.
Methods A computational modeling approach based on ordinary differential equations was used to simulate the fundamental mechanisms that dictate tumor-immune dynamics and show its implications on responses to immune checkpoint inhibition (ICI) and patient survival. Using in silico biomarker discovery trials, we extracted fundamental principles underlying the success rates of biomarker discovery programs.
Results Our main finding is the prediction of a tipping point – a sharp state transition between immune control and immune evasion – that follows a strongly non-linear relationship between patient survival and both immunological and tumor-related parameters. In patients close to the tipping point, ICI therapy may lead to long-lasting survival benefits, whereas patients far from the tipping point may fail to benefit from these potent treatments.
Conclusion These findings have two important implications for clinical oncology. First, the apparent conundrum that ICI induces substantial benefits in some patients yet completely fails in others could be, to a large extent, explained by the presence of a tipping point. Second, predictive biomarkers for immunotherapy should ideally combine both immunological and tumor-related markers, as the distance of a patient’ status from the tipping point cannot, in general, be reliably determined from solely one of these. The notion of a tipping point in cancer-immune dynamics could help to optimize strategies in biomarker discovery to ensure accurate selection of the right patient for the right treatment.
Competing Interest Statement
WL reports consultancy activities for Douglas Pharmaceuticals and MSD; research funding from Douglas Pharmaceuticals, AstraZeneca, and ENA therapeutics; patents PCT/AU2019/050259 and PCT/AU2015/000458 (all outside this work). NM reports personal fees from Bayer and Merck Sharp & Dohme; grants and personal fees from Jansen-Cilag, Roche, Astellas, and Sanofi (all outside this work). WG reports consultancy activities for Bristol-Myers Squibb, IMS Health, Janssen-Cilag, Sanofi, and MSD; speaker fees from ESMO and MSD; and research funding from Bayer, Astellas, Janssen-Cilag, and Sanofi (all outside this work).
Funding Statement
JC was funded by the Radboudumc. WL was supported by Fellowships from the NHMRC, the Simon Lee Foundation, and the Cancer Council Western Australia. CF received an ERC Adv Grant ARTimmune (834618) and an NWO Spinoza grant. IV received an NWO-Vici grant (918.14.655). JT was supported by a Young Investigator Grant (10620) from the Dutch Cancer Society and an NWO grant (VI.Vidi.192.084).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The code of the ODE model is available at GitHub.
https://github.com/jeroencreemers/tipping-point-cancer-immune-dynamics.
LIST OF ABBREVIATIONS
- ICI
- Immune Checkpoint Inhibition
- ODE
- Ordinary Differential Equation
- PD-(L)1
- Programmed Death-(Ligand) 1
- TMB
- Tumor Mutational Burden
